Table 1.
Entire Population | 5-ALA | SF | 5-ALA + SF | |
---|---|---|---|---|
99 | 40 | 44 | 15 | |
Age | 62.3 ± 9.6 | 63.9 ± 9.5 | 60.8 ± 9.9 | 61.7 ± 8.7 |
Sex | F:M 50(50.5%):49(49.5%) | 19(47.5%):21(52.5%) | 23(52.3%):21(47.7%) | 8(53%):7(47%) |
Left:Right Sided | 50(50.5%):49(49.5%) | 22(55%):18(45%) | 21(47.7%):23(52.3%) | 7(47%):8(53%) |
Precentral:Postcentral:Temporo-insular | 30(30.3%):35(35.4%):34(34.3%) | 14(35%):12(30%):14(35%) | 11(25%):17(38.6%):16(36.4%) | 5(33.3%):6(40%):4(26.6%) |
Preoperative KPS | 92.7 ± 9.9 | 91.9 ± 10.4 | 92.9 ± 10.3 | 95 ± 7.5 |
Postoperative KPS | 87.5 ± 13.9 | 84.3 ± 16.6 | 90.6 ± 10.8 | 89.6 ± 9.4 |
Preoperative CE-T1w Volume | 40.8 ± 29.4 cm3 | 43.9 ± 31.7 cm3 | 32.2 ± 23.2 cm3 | 48.8 ± 29.5 cm3 |
Postoperative CE-T1w Volume | 0.42 ± 8.4 cm3 | 2.3 ± 11.4 cm3 | 3.3 ± 3 cm3 | 3.5 ± 0.4 cm3 |
MGMT Promoter Status | 51 (51.5%) methylated | 23 (57.5%) methylated | 21 (47.4%) methylated | 7 (47%) methylated |
OS | 14.9 ± 9.91 months | 20 ± 16 months | 12.3 ± 5.7 months | 18.1 ± 11.9 months |